NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings data on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.01. The medical research company earned $104.70 million during the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. NeoGenomics's quarterly revenue was up 51.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.05 EPS. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics.

6 Wall Street analysts have issued 1 year price objectives for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they anticipate NeoGenomics' stock price to reach $25.60 in the next twelve months. This suggests that the stock has a possible downside of 3.8%. View Analyst Price Targets for NeoGenomics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

Headlines about NEO stock have been trending extremely negative on Thursday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. NeoGenomics earned a news impact score of -4.0 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the near term. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest in October. As of October 31st, there was short interest totalling 6,450,000 shares, an increase of 14.4% from the September 30th total of 5,640,000 shares. Based on an average trading volume of 770,800 shares, the short-interest ratio is currently 8.4 days. Currently, 6.5% of the shares of the company are sold short. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include BioMerieux (BMXMF), Teva Pharmaceutical Industries (TEVA), Insulet (PODD), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), Avantor (AVTR), Neurocrine Biosciences (NBIX), Bausch Health Companies (BHC), Bio-Rad Laboratories (BIO.B), Henry Schein (HSIC), Elanco Animal Health (ELAN), Carl Zeiss Meditec (AFX), Eurofins Scientific (ERFSF), Mylan (MYL) and Ono Pharmaceutical (OPHLF).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), Intel (INTC), Netflix (NFLX), AbbVie (ABBV), CVS Health (CVS), Exelixis (EXEL) and AT&T (T).

NeoGenomics' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (2.59%), Eagle Asset Management Inc. (2.59%), Emerald Mutual Fund Advisers Trust (1.71%), Emerald Advisers LLC (1.67%), Granahan Investment Management Inc. MA (0.94%) and Russell Investments Group Ltd. (0.55%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Castleark Management LLC, Rice Hall James & Associates LLC, First Trust Advisors LP, Gabelli Funds LLC, Robeco Institutional Asset Management B.V. and Russell Investments Group Ltd.. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, George Cardoza, Jennifer Balliet, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, New York State Teachers Retirement System, Squarepoint Ops LLC, Granahan Investment Management Inc. MA and State of Alaska Department of Revenue. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $26.62.

NeoGenomics has a market capitalization of $2.78 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]